Compare PT & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PT | AYTU |
|---|---|---|
| Founded | 2012 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7M | 23.4M |
| IPO Year | 2018 | N/A |
| Metric | PT | AYTU |
|---|---|---|
| Price | $0.92 | $2.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 67.7K | ★ 98.6K |
| Earning Date | 09-19-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,961,892.00 | ★ $63,696,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $47.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.20 | N/A |
| 52 Week Low | $0.76 | $0.95 |
| 52 Week High | $1.38 | $2.82 |
| Indicator | PT | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 40.28 | 64.74 |
| Support Level | $0.92 | $2.42 |
| Resistance Level | $0.99 | $2.59 |
| Average True Range (ATR) | 0.05 | 0.15 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 13.48 | 87.50 |
Pintec Technology Holdings Ltd is a technology platform that provides financial services in China in terms of loan volume facilitated. The company connects business partners and financial partners on its open platform and enables them to provide financial services to end-users. Its products include installment loans, personal loans, wealth management, insurance brokerage, SME loans, and others. The company generates its revenue from technical service fees, as well as by providing financing for these borrowers and earning installment service fees. The company earns wealth management services fees and commissions on financial products. The company generates the majority of its revenue from Wealth management service fees and others.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.